Published in Bioorg Med Chem on February 16, 2012
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther (2013) 0.87
Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy. Clin Cancer Res (2013) 0.85
In Vitro and In Vivo Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis. Antimicrob Agents Chemother (2016) 0.79
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. J Med Chem (2016) 0.79
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study. J Med Chem (2016) 0.76
A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβ. Immunol Lett (2015) 0.75
Cell death: critical control points. Cell (2004) 22.56
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (1996) 8.37
Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell (2002) 5.31
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ (2000) 4.34
Structural basis for the inhibition of caspase-3 by XIAP. Cell (2001) 3.91
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
Caspases: the proteases of the apoptotic pathway. Oncogene (1998) 3.11
BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem (2002) 3.05
Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol (2010) 3.01
Structural basis of caspase-7 inhibition by XIAP. Cell (2001) 2.99
Mcl-1; the molecular regulation of protein function. FEBS Lett (2010) 2.71
Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol (1997) 2.07
Clinical practice. Treating smokers in the health care setting. N Engl J Med (2011) 1.99
Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med Chem Lett (2004) 1.82
Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochem J (2002) 1.71
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64
IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle (2008) 1.63
Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res (2007) 1.59
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.35
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res (2008) 1.35
Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ (2010) 1.32
Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem (2010) 1.32
Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs (2010) 1.32
Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem (2006) 1.25
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem (2007) 1.18
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci U S A (2008) 1.13
QUINACILLIN: A COMPARISON WITH OTHER PENICILLINASE-RESISTANT PENICILLINS. Nature (1964) 1.06
Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res (2005) 1.05
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood (2008) 1.00
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 1.00
GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett (2011) 0.95
Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies. Nat Prod Rep (2006) 0.94
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer (2008) 0.94
Recent developments in bisintercalator natural products. Biopolymers (2010) 0.90
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorg Med Chem Lett (2011) 0.90
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma (1997) 0.87
Izumiphenazines A-C: isolation and structure elucidation of phenazine derivatives from Streptomyces sp. IFM 11204. J Nat Prod (2010) 0.86
2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study. Bioorg Med Chem Lett (2011) 0.86
Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol (2005) 0.85
Synthesis and biological activities of pyrazolo[3,4-g]quinoxaline derivatives. Eur J Med Chem (2010) 0.82
Synthesis and evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors. Bioorg Med Chem Lett (2011) 0.81
Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer (2003) 0.80
Divergent synthesis of unsymmetrical annulated biheterocyclic compound libraries: benzimidazole linked indolo-benzodiazepines/quinoxaline. ACS Comb Sci (2011) 0.79
A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev (2007) 1.97
Hydrogen therapy reduces apoptosis in neonatal hypoxia-ischemia rat model. Neurosci Lett (2008) 1.71
Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. Brain Res (2008) 1.60
Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther (2008) 1.43
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem (2010) 1.32
High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Anal Biochem (2006) 1.20
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem (2007) 1.18
Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. J Am Chem Soc (2007) 1.14
Bax contains two functional mitochondrial targeting sequences and translocates to mitochondria in a conformational change- and homo-oligomerization-driven process. J Biol Chem (2009) 1.10
The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo. PLoS One (2013) 1.08
Changes in reproductive physiology of lactating dairy cows due to elevated steroid metabolism. Theriogenology (2005) 1.04
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget (2011) 1.01
Structural characterization of BRCT-tetrapeptide binding interactions. Biochem Biophys Res Commun (2010) 1.01
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 1.00
Sox2 uses multiple domains to associate with proteins present in Sox2-protein complexes. PLoS One (2010) 0.94
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol (2006) 0.94
Pulse design for broadband correlation NMR spectroscopy by multi-rotating frames. J Biomol NMR (2013) 0.91
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorg Med Chem Lett (2011) 0.90
Pivotal role of inosine triphosphate pyrophosphatase in maintaining genome stability and the prevention of apoptosis in human cells. PLoS One (2012) 0.89
High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem (2010) 0.89
Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1. J Med Chem (2011) 0.89
Identification of the DNA-Binding Domains of Human Replication Protein A That Recognize G-Quadruplex DNA. J Nucleic Acids (2011) 0.88
Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat (2012) 0.88
Active Bax and Bak are functional holins. Genes Dev (2011) 0.87
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther (2013) 0.87
Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. ACS Med Chem Lett (2011) 0.87
2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study. Bioorg Med Chem Lett (2011) 0.86
Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1. J Comput Aided Mol Des (2011) 0.85
Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins. Biochem Anal Biochem (2012) 0.85
Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. J Med Chem (2012) 0.85
Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy. Clin Cancer Res (2013) 0.85
The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides. Sci Rep (2013) 0.85
Axial SiGe heteronanowire tunneling field-effect transistors. Nano Lett (2012) 0.85
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. J Med Chem (2014) 0.84
BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci (2005) 0.84
Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett (2004) 0.84
High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity. Anal Biochem (2013) 0.82
Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS. Biomed Chromatogr (2013) 0.82
Lineage diversification and historical demography of a montane bird Garrulax elliotii--implications for the Pleistocene evolutionary history of the eastern Himalayas. BMC Evol Biol (2011) 0.82
The heparin binding motif of endostatin mediates its interaction with receptor nucleolin. Biochemistry (2009) 0.81
Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase. J Med Chem (2013) 0.80
Helium preconditioning attenuates hypoxia/ischemia-induced injury in the developing brain. Brain Res (2010) 0.79
[Effect of bizhongxiao decotion on TNF-alpha and interleukin-1beta in plasma of rats with C II-induced rheumatoid arthritis]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2004) 0.78
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg Med Chem Lett (2004) 0.78
Face selective reduction of the exocyclic double bond in isatin derived spirocyclic lactones. Org Biomol Chem (2012) 0.77
Protein-protein interactions as therapeutic targets in neuropsychopharmacology. Neuropsychopharmacology (2009) 0.77
An HPLC method for the determination and pharmacokinetic study of cinnamic acid in the plasma of rats having taken the traditional Chinese medicinal preparation Ling-Gui-Zhu-Gan decoction. J Chromatogr Sci (2002) 0.77
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study. J Med Chem (2016) 0.76
Synthesis of conformationally constrained lysine analogues. J Org Chem (2006) 0.76
Irreversible binding of an anticancer compound (BI-94) to plasma proteins. Xenobiotica (2015) 0.75
Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides. Bioorg Med Chem Lett (2007) 0.75
Beyond the frog: the evolution of homology models of human IKKβ. Bioorg Med Chem Lett (2011) 0.75
Effect of Bizhongxiao Decotion (BZXD) on Some Cytokines in Plasma of Rats with CII-induced Rheumatoid Arthritis. Int J Biomed Sci (2005) 0.75
Synthesis of unnatural amino acid derivatives via palladium catalyzed 1,4 addition of boronic acids. Tetrahedron Lett (2010) 0.75
[Construction and evaluation of the epidemiological injury criteria based on the combination of 'Hurt' and 'Harm']. Nan Fang Yi Ke Da Xue Xue Bao (2016) 0.75
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) (2017) 0.75
[Influence of fire disturbance on aboveground deadwood debris carbon storage in Huzhong forest region of Great Xing'an Mountains, Northeast China]. Ying Yong Sheng Tai Xue Bao (2015) 0.75
Decontamination of organochlorine pesticides in Radix codonopsis by supercritical fluid extractions and determination by gas chromatography. Biomed Chromatogr (2006) 0.75
High-performance liquid chromatographic method for the determination and pharmacokinetic study of dehydrotumulosic acid in the plasma of rats having taken the traditional chinese medicinal preparation Ling-Gui-Zhu-Gan decoction. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75
[Effects of sampling plot number on tree species distribution prediction under climate change]. Ying Yong Sheng Tai Xue Bao (2013) 0.75
Osteopontin as a potential therapeutic target for ischemic stroke. Curr Drug Deliv (2016) 0.75
[The influence of endotracheal tube cuff pressures to PEEP values in mechanical ventilated patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue (2009) 0.75
[Impact of preservation of distal prostatic capsula and seminal vesicle on functions of orthotopic ideal neobladder and erectile function of bladder cancer patients]. Ai Zheng (2008) 0.75
Comparative Study on the Roles of the Number of Accelerations and Rotation Angle in the Treatment Maneuvers for Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo. ORL J Otorhinolaryngol Relat Spec (2015) 0.75
[Establishment of standard forest fuel models for Fenglin Natural Reserve, Heilongjiang Province, China]. Ying Yong Sheng Tai Xue Bao (2012) 0.75
The isolation, identification and determination of dehydrotumulosic acid in Poria cocos. Anal Sci (2002) 0.75
Sediment Profile and Fluxes of Mercury and Methyl Mercury in Weihe Watershed in Henan, China. Bull Environ Contam Toxicol (2015) 0.75